An Open-label, Multicenter, Dose-escalation, Randomized, Phase I Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Anti-Tumor Activity of RO7567132, as a Single Agent and in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Latest Information Update: 15 Mar 2025
At a glance
- Drugs Atezolizumab (Primary) ; RG 6221 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Roche
Most Recent Events
- 19 Sep 2024 Planned initiation date changed from 9 Sep 2024 to 16 Sep 2024.
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 13 Aug 2024 New trial record